Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

Inclusion Criteria:

Participants must meet all of the following criteria to be enrolled in the study:

1. Voluntarily participate in the trial and sign the informed consent; Willing andable, in the investigator's judgment, to comply with all experimentalrequirements and restrictions;

2. Healthy men and women, aged 18 to 55 years old (including);

3. Body mass index (BMI) 19.0~25.0 kg/m2 (including), weight ≥50.0 kg;

4. Physical examination, vital signs, 12-lead electrocardiogram (ECG), clinicallaboratory examination, no clinically significant abnormalities;

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded:

1. Have a history of clinically serious disease or currently have any clinicallysignificant cardiovascular, metabolic, endocrine, kidney, liver, gastrointestinal,hematological, respiratory, cutaneous, neurological, gynecological, psychiatric orother disease;

2. A history of medullary thyroid carcinoma (MTC), multiple endocrine adenoma (MEN) 2Aor 2B syndrome, or related family history; Or other malignant tumor history;

3. Subjects with a history of acute and chronic pancreatitis, symptomatic gallbladderhistory, pancreatic injury history and other high-risk factors that may lead topancreatitis;

4. In the screening period, calcitonin was greater than the upper limit of normal;

5. Patients with HbA1c greater than 6.5% during the screening period;

6. Those who smoked more than 5 cigarettes per day in the 3 months before screening andthose who could not smoke during the whole test period;

7. Those who have a history of alcohol abuse in the six months prior to screening, orwho cannot abstain from alcohol during the test period;

8. Consume any food or drink containing caffeine, alcohol, xanthine or grapefruit (suchas coffee, strong tea, chocolate, etc.) within 48 hours before check-in;

9. Known or suspected allergy to semaglutide injection or similar products andexcipients;

10. Participants in clinical trials of any approved or unapproved investigationaldrug/device within 90 days prior to screening;

11. Pregnant and lactating female subjects;

12. Patients with difficulty in venous blood collection;

13. Those who were vaccinated within 4 weeks prior to screening or planned to bevaccinated during the trial;

14. People who donate blood or lose more than 400 mL of blood or receive bloodtransfusions or use blood products in the 3 months prior to screening;

15. Patients who have previously received Semaglutide injection or other GLP-1 or GLP-1/GIP-like treatment;

16. Those who have a history of drug abuse or test positive for drug abuse screening;

17. Those who test positive for blood alcohol;

18. For any other reason, the investigator does not consider the volunteer to besuitable for participation in this clinical trial.